Outcomes in patients with MF in MPD-RC 101
| . | Sibling donor (n = 32) . | Unrelated donor (n = 34) . |
|---|---|---|
| Primary graft failure, n (%) | 1 (3%) | 8 (24%) |
| Patients with ANC ≥0.5 × 109/L, n | 31 | 26 |
| Days to ANC engraftment, median (range) | 22 (0-62) | 18 (11-43) |
| Patients with PLT ≥20 × 109/L, n | 28 | 20 |
| Days to PLT engraftment, median (range) | 28 (0-62) | 29 (9-365) |
| Secondary graft failure, n (%) | 1 (3%) | 4 (12%) |
| aGVHD grade II-IV, % | 12 (38%) | 14 (41%) |
| aGVHD grade III-IV, n % | 4 (13%) | 7 (21%) |
| cGVHD, n % | 10/28 (36%) | 5/15 (38%) |
| Patients alive, n (%) | 24 (75%) | 11 (32%) |
| Deaths <6 mo, n (%) | 3 (9%) | 17 (50%) |
| Clinical response, n (%) | 29 | 17 |
| Overall response rate, n (%) | 26/28 (93%) | 11 (69%) |
| Clinical CR, n (%) | 7 (24%) | 6 (35%) |
| PR, n (%) | 8 (28%) | 1 (6%) |
| Clinical improvement, n (%) | 11 (38%) | 5 (29%) |
| Stable disease, n (%) | 2 (7%) | 4 (24%) |
| Progressive disease, n (%) | 0 | 1 (6%) |
| Unknown response, n (%) | 1 (3%) | — |
| . | Sibling donor (n = 32) . | Unrelated donor (n = 34) . |
|---|---|---|
| Primary graft failure, n (%) | 1 (3%) | 8 (24%) |
| Patients with ANC ≥0.5 × 109/L, n | 31 | 26 |
| Days to ANC engraftment, median (range) | 22 (0-62) | 18 (11-43) |
| Patients with PLT ≥20 × 109/L, n | 28 | 20 |
| Days to PLT engraftment, median (range) | 28 (0-62) | 29 (9-365) |
| Secondary graft failure, n (%) | 1 (3%) | 4 (12%) |
| aGVHD grade II-IV, % | 12 (38%) | 14 (41%) |
| aGVHD grade III-IV, n % | 4 (13%) | 7 (21%) |
| cGVHD, n % | 10/28 (36%) | 5/15 (38%) |
| Patients alive, n (%) | 24 (75%) | 11 (32%) |
| Deaths <6 mo, n (%) | 3 (9%) | 17 (50%) |
| Clinical response, n (%) | 29 | 17 |
| Overall response rate, n (%) | 26/28 (93%) | 11 (69%) |
| Clinical CR, n (%) | 7 (24%) | 6 (35%) |
| PR, n (%) | 8 (28%) | 1 (6%) |
| Clinical improvement, n (%) | 11 (38%) | 5 (29%) |
| Stable disease, n (%) | 2 (7%) | 4 (24%) |
| Progressive disease, n (%) | 0 | 1 (6%) |
| Unknown response, n (%) | 1 (3%) | — |
Engraftment, GVHD, and survival data are shown. Primary graft failure is defined as lack of engraftment of donor neutrophils and secondary graft failure as loss of the graft. Clinical response was assessed according to the IWG criteria in patients with at least 180 days of follow-up.
ANC, absolute neutrophil count; PLT, platelet.